NEUROCRINE BIOSCIENCES INC
Simply Wall St says Neurocrine Biosciences (NBIX) reported Q2 2026 revenue of $959 million and net income of $144.4 million. It also filed a $742 million shelf registration for 4,000,000 common shares tied to an ESOP offering. The piece links stronger profitability and potential dilution to investor expectations around INGREZZA and CRENESSITY.
Neurocrine Biosciences (NBIX) said it has started a Phase 1 first-in-human clinical study of NBIP-’1968 to assess safety and tolerability. The company described the program as part of its obesity and metabolic disease pipeline.
Neurocrine Biosciences (Nasdaq: NBIX) said it has started a Phase 1 first-in-human study of NBIP-'1968, an investigational GLP-1/GIP/glucagon triple agonist for obesity. The trial will assess single ascending doses for safety and tolerability in adults across BMI categories, with once-weekly subcutaneous dosing. NBIP-'1968 is planned as a fixed-dose combination with NBIP-'2118.
Over the past 7 days, alphai's AI scored 3 news stories mentioning NBIX (NEUROCRINE BIOSCIENCES INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent NBIX coverage spans earnings, insider activity and technology.
In the last 30 days, NBIX insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($4.3M). The most active reporter was Delaet Ingrid, Chief Regulatory Officer, with 2 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Higher reported profitability alongside fresh equity capacity shifts the near-term balance between earnings momentum and potential dilution risk.
Phase 1 initiation is an early clinical milestone that can improve perceived pipeline progress, but it is not yet efficacy- or approval-relevant.
Phase 1 initiation is a meaningful pipeline milestone that can improve sentiment and de-risk near-term development, but it is not yet efficacy- or safety-data.
Raised INGREZZA guidance and clearer VYKAT XR trajectory should support near-term estimates, while 2027-2028 EPS variability and upcoming Phase 3 catalysts drive longer-dated optionality.
Raised INGREZZA guidance plus multiproduct scaling (CRENESSITY and VYKAT XR) and a debt-free $2.9B cash acquisition frame a near-term earnings upside with longer-dated Phase 3 catalysts in 2H 2027.
alphai scores every news story that mentions NBIX with an AI model for sentiment and relevance, and aggregates insider trades from NEUROCRINE BIOSCIENCES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Simply Wall St says Neurocrine Biosciences (NBIX) reported Q2 2026 revenue of $959 million and net income of $144.4 million. It also filed a $742 million shelf registration for 4,000,000 common shares tied to an ESOP offering. The piece links stronger profitability and potential dilution to investor expectations around INGREZZA and CRENESSITY.
4 min readNeurocrine Biosciences (NBIX) said it has started a Phase 1 first-in-human clinical study of NBIP-’1968 to assess safety and tolerability. The company described the program as part of its obesity and metabolic disease pipeline.
2 min readNeurocrine Biosciences (Nasdaq: NBIX) said it has started a Phase 1 first-in-human study of NBIP-'1968, an investigational GLP-1/GIP/glucagon triple agonist for obesity. The trial will assess single ascending doses for safety and tolerability in adults across BMI categories, with once-weekly subcutaneous dosing. NBIP-'1968 is planned as a fixed-dose combination with NBIP-'2118.
2 min readNeurocrine Biosciences reported Q2 2026 results and discussed its shift to a diversified portfolio. Management said INGREZZA record new patient additions supported raised full-year guidance midpoint for 13% YoY growth. CRENESSITY launch progress and Soleno and VYKAT XR acquisitions were highlighted. Soleno was $2.9B cash-funded; quarter-end cash was $500M and no debt.
7 min readThursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Tushla Chief Executive Officer - Kyle W. Gano Chief Financial Officer - Matthew Abernethy Chief Commercial Officer - Eric S. Benevich Chief Medical Officer - Sanjay Keswani Chief Business Officer - Samir Siddhanti Need a quote from a Motley Fool analyst?
7 min readNEUROCRINE BIOSCIENCES INC (NBIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q2-2026xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to
6 min readNeurocrine Biosciences (Nasdaq: NBIX) appointed Samir Siddhanti as Chief Business Officer and an executive Management Committee member. He will lead enterprise growth, including business development, corporate strategy, alliance and program management. The release says he joined in 2017 and helped lead deals, including the company’s $2.9 billion Soleno Therapeutics acquisition.
2 min readDelaet Ingrid (Chief Regulatory Officer) sold 4,367 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $181.02 ($0.79M total) on 2026-07-10 under a Rule 10b5-1 trading plan.
1 min readLippoldt Darin (Chief Legal Officer) sold 10,000 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $179.60 ($1.80M total) on 2026-07-09 under a Rule 10b5-1 trading plan.
2 min readDelaet Ingrid (Chief Regulatory Officer) sold 14,571 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at an average of $178.65 ($178.54–$178.72, $2.60M total) across 3 trades over 2026-07-07 to 2026-07-09 under a Rule 10b5-1 trading plan.
1 min read
